Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for today's call. [Operator Instructions] Please note that this ...
If the novel factor XI inhibitor abelacimab reaches the market for patients with atrial fibrillation (AF) who require anticoagulation, it may not be necessary to interrupt treatment ahead of invasive ...
The oral factor XIa inhibitor milvexian across a range of doses is associated with a lower risk of venous thromboembolism (VTE) after knee arthroplasty than subcutaneous enoxaparin (Lovenox) without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results